Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: UTR056
MIFTS: 26

Uterine Corpus Endometrial Carcinoma malady

Categories: Cancer diseases, Reproductive diseases
Genes Tissues Related diseases Pathways Drugs
Sources

Aliases & Classifications for Uterine Corpus Endometrial Carcinoma

About this section

Aliases & Descriptions for Uterine Corpus Endometrial Carcinoma:

Name: Uterine Corpus Endometrial Carcinoma 12 14

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0050939
Sources

Summaries for Uterine Corpus Endometrial Carcinoma

About this section
Disease Ontology : 12 A uterine corpus cancer that is derives from the inner lining of the uterus.

MalaCards based summary : Uterine Corpus Endometrial Carcinoma is related to acrofrontofacionasal dysostosis and intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies. An important gene associated with Uterine Corpus Endometrial Carcinoma is PPP3CA (Protein Phosphatase 3 Catalytic Subunit Alpha), and among its related pathways/superpathways are Spinal Cord Injury and Amyotrophic lateral sclerosis (ALS). The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include uterus, and related phenotype is renal/urinary system.

Sources

Related Diseases for Uterine Corpus Endometrial Carcinoma

About this section

Diseases related to Uterine Corpus Endometrial Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 19)
id Related Disease Score Top Affiliating Genes
1 acrofrontofacionasal dysostosis 10.1 PPP3CA TP53
2 intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies 10.0 CYP11B1 CYP11B2
3 cardiomyopathy, dilated, 1v 10.0 CYP11B1 CYP11B2
4 hypoaldosteronism, congenital, due to cmo i deficiency 10.0 CYP11B1 CYP11B2
5 jackson-weiss syndrome 10.0 CYP11B1 CYP11B2
6 benign peritoneal mesothelioma 10.0 CYP11B1 CYP11B2
7 merkel cell carcinoma 10.0 CYP11B1 CYP11B2
8 esophagus squamous cell papilloma 10.0 CYP11B1 CYP11B2
9 panuveitis 10.0 CYP11B1 CYP11B2
10 gliosarcoma 10.0 PPIG TP53
11 immune system organ benign neoplasm 9.9 CYP11B1 CYP11B2
12 clear cell adenocarcinoma 9.9 CYP11B1 CYP11B2
13 vestibular gland benign neoplasm 9.9 CYP11B2 TP53
14 childhood optic tract astrocytoma 9.9 CYP11B1 CYP11B2
15 glioma susceptibility 1 9.8 CYP11B1 CYP11B2 TP53
16 endocrine organ benign neoplasm 9.8 CYP11B1 CYP11B2 TP53
17 bladder colonic type adenocarcinoma 9.8 CYP11B1 CYP11B2 TP53
18 second-degree atrioventricular block 9.8 CYP11B1 CYP11B2
19 spastic ataxia 3 9.3 CYP11B1 CYP11B2 PPIG PPP3CA TP53

Graphical network of the top 20 diseases related to Uterine Corpus Endometrial Carcinoma:



Diseases related to Uterine Corpus Endometrial Carcinoma
Sources

Symptoms & Phenotypes for Uterine Corpus Endometrial Carcinoma

About this section

MGI Mouse Phenotypes related to Uterine Corpus Endometrial Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 8.92 CYP11B1 CYP11B2 PPP3CA TP53
Sources

Drugs & Therapeutics for Uterine Corpus Endometrial Carcinoma

About this section

Drugs for Uterine Corpus Endometrial Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 117)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
2
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 498142 38904
3
Ifosfamide Approved Phase 3 3778-73-2 3690
4
Mechlorethamine Approved Phase 3 51-75-2 4033
5
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
6
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
7
Lenograstim Approved Phase 3,Phase 1 135968-09-1
8
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
9
Succinylcholine Approved Phase 3,Phase 2,Phase 1 306-40-1 5314
10
Menthol Approved Phase 3 2216-51-5 16666
11
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
12 Alkylating Agents Phase 3
13 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
14 Isophosphamide mustard Phase 3
15 Antimitotic Agents Phase 3,Phase 2,Phase 1
16 Antineoplastic Agents, Alkylating Phase 3
17 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
18 Adjuvants, Immunologic Phase 3,Phase 1
19 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
20 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
21 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
22 Neuromuscular Agents Phase 3,Phase 2,Phase 1
23 Neuromuscular Blocking Agents Phase 3,Phase 2,Phase 1
24 Neuromuscular Depolarizing Agents Phase 3,Phase 2,Phase 1
25 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
26 Hypoglycemic Agents Phase 2, Phase 3
27
Tamoxifen Approved Phase 2 10540-29-1 2733526
28
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
29
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
30
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
31
Everolimus Approved Phase 2 159351-69-6 6442177
32
Megestrol acetate Approved, Vet_approved Phase 2 595-33-5 11683
33
Medroxyprogesterone acetate Approved, Investigational Phase 2 71-58-9
34
Nintedanib Approved Phase 2 656247-17-5 56843413
35
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
36
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
37
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
38
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
39
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757 53477783
40
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
41
Fulvestrant Approved, Investigational Phase 2 129453-61-8 104741 17756771
42
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
43
Trametinib Approved Phase 2 871700-17-3 11707110
44
Acetaminophen Approved Phase 2 103-90-2 1983
45
Camptothecin Experimental Phase 2 7689-03-4
46
Cediranib Investigational Phase 2 288383-20-0 9933475
47
Maleic acid Experimental Phase 2 110-16-7 444266
48
Epothilone B Experimental, Investigational Phase 2 152044-54-7
49
Megestrol Phase 2 3562-63-8 19090 3080587
50
Medroxyprogesterone Phase 2 520-85-4 10631

Interventional clinical trials:

(show top 50) (show all 65)
id Name Status NCT ID Phase
1 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Unknown status NCT00954174 Phase 3
2 Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus Completed NCT00002706 Phase 3
3 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3
4 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Recruiting NCT02065687 Phase 2, Phase 3
5 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3
6 Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Active, not recruiting NCT00063999 Phase 3
7 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3
8 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3
9 Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer Terminated NCT00577317 Phase 3
10 Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer Unknown status NCT02112552 Phase 2
11 Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT00027690 Phase 2
12 Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC) Completed NCT00249990 Phase 2
13 Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01011933 Phase 2
14 Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00820898 Phase 2
15 Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer Completed NCT00729586 Phase 2
16 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01132820 Phase 2
17 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2
18 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
19 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT01210222 Phase 2
20 Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus Completed NCT00064025 Phase 2
21 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2
22 Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Recruiting NCT00492778 Phase 2
23 Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Recruiting NCT01935934 Phase 2
24 Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer Recruiting NCT01041027 Phase 2
25 Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer Recruiting NCT02657928 Phase 2
26 Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer Recruiting NCT02728258 Phase 2
27 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2
28 Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer Active, not recruiting NCT00006903 Phase 2
29 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT00478426 Phase 2
30 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Active, not recruiting NCT01307631 Phase 2
31 Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Active, not recruiting NCT00977574 Phase 2
32 Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Active, not recruiting NCT01935973 Phase 2
33 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Active, not recruiting NCT00888173 Phase 2
34 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Active, not recruiting NCT01010126 Phase 2
35 Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Active, not recruiting NCT02059265 Phase 2
36 Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer Not yet recruiting NCT03018249 Phase 2
37 Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia Terminated NCT00503581 Phase 2
38 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00005840 Phase 1
39 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00005830 Phase 1
40 Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRa-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer Recruiting NCT02996825 Phase 1
41 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Recruiting NCT02020707 Phase 1
42 TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Recruiting NCT02142803 Phase 1
43 Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer Active, not recruiting NCT00575952 Phase 1
44 VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer Not yet recruiting NCT03120624 Phase 1
45 Sentinel Node Biopsy in Endometrial Cancer Unknown status NCT01564264
46 Aerosolized Liposomal Camptothecin in Patients With Metastatic or Recurrent Cancer of the Endometrium or the Lung Completed NCT00277082
47 Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin (L9NC) Completed NCT00250016
48 Pre-Clinical Models in Gynecological Tumors A Tissue Repository Completed NCT00250783
49 Toxicities of Cervix and Corpus Uteri Carcinomas Treatment and Evaluation of Impact on Sexual Function Completed NCT01650987
50 Collecting Tumor Samples From Patients With Gynecological Tumors Completed NCT00897442

Search NIH Clinical Center for Uterine Corpus Endometrial Carcinoma

Sources

Genetic Tests for Uterine Corpus Endometrial Carcinoma

About this section
Sources

Anatomical Context for Uterine Corpus Endometrial Carcinoma

About this section

MalaCards organs/tissues related to Uterine Corpus Endometrial Carcinoma:

39
Uterus
Sources

Publications for Uterine Corpus Endometrial Carcinoma

About this section
Sources

Variations for Uterine Corpus Endometrial Carcinoma

About this section
Sources

Expression for Uterine Corpus Endometrial Carcinoma

About this section
Search GEO for disease gene expression data for Uterine Corpus Endometrial Carcinoma.
Sources

Pathways for Uterine Corpus Endometrial Carcinoma

About this section

Pathways related to Uterine Corpus Endometrial Carcinoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Spinal Cord Injury 1
11.45 PPP3CA TP53
2
Amyotrophic lateral sclerosis (ALS) 1 37
Show member pathways
 11.38 PPP3CA TP53
3
Metabolism of steroid hormones 62
Show member pathways
 11.2 CYP11B1 CYP11B2
4
MAPK Signaling: Oxidative Stress Pathway 61
11.09 PPP3CA TP53
5
Steroid hormone biosynthesis 37
Show member pathways
 10.76 CYP11B1 CYP11B2
6
superpathway of steroid hormone biosynthesis 1
Show member pathways
 9.95 CYP11B1 CYP11B2
Sources

GO Terms for Uterine Corpus Endometrial Carcinoma

About this section

Cellular components related to Uterine Corpus Endometrial Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 mitochondrial membrane GO:0031966 9.16 CYP11B1 CYP11B2
2 nuclear matrix GO:0016363 8.96 PPIG TP53
3 mitochondrion GO:0005739 8.92 CYP11B1 CYP11B2 PPP3CA TP53

Biological processes related to Uterine Corpus Endometrial Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 steroid metabolic process GO:0008202 9.46 CYP11B1 CYP11B2
2 cellular response to drug GO:0035690 9.43 PPP3CA TP53
3 steroid biosynthetic process GO:0006694 9.4 CYP11B1 CYP11B2
4 cellular response to hormone stimulus GO:0032870 9.37 CYP11B1 CYP11B2
5 sterol metabolic process GO:0016125 9.32 CYP11B1 CYP11B2
6 C21-steroid hormone biosynthetic process GO:0006700 9.26 CYP11B1 CYP11B2
7 cellular response to potassium ion GO:0035865 9.16 CYP11B1 CYP11B2
8 aldosterone biosynthetic process GO:0032342 8.96 CYP11B1 CYP11B2
9 cortisol biosynthetic process GO:0034651 8.62 CYP11B1 CYP11B2

Molecular functions related to Uterine Corpus Endometrial Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 iron ion binding GO:0005506 9.37 CYP11B1 CYP11B2
2 heme binding GO:0020037 9.32 CYP11B1 CYP11B2
3 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.26 CYP11B1 CYP11B2
4 cyclosporin A binding GO:0016018 9.16 PPIG PPP3CA
5 corticosterone 18-monooxygenase activity GO:0047783 8.96 CYP11B1 CYP11B2
6 steroid 11-beta-monooxygenase activity GO:0004507 8.62 CYP11B1 CYP11B2
Sources

Sources for Uterine Corpus Endometrial Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....